Sermorelin is not testosterone replacement therapy. It acts through growth hormone-releasing signaling, while TRT supplies testosterone. Similar advertising around energy or muscle does not make the treatments interchangeable.
There is not compelling evidence to present sermorelin as a reliable way to correct testosterone deficiency. If low testosterone, sexual symptoms, or fertility are the concern, they need their own evaluation rather than a peptide chosen from a wellness menu.
Evaluate growth hormone and testosterone questions separately. Combining treatments requires a reason for each one.
A testosterone diagnosis requires more than a symptom
The Endocrine Society recommends diagnosing hypogonadism in men with relevant symptoms and consistently, unequivocally low testosterone measurements, with further evaluation of the cause. Fatigue by itself is not that diagnosis.
Sermorelin should not be advertised as a substitute for that process. Ask whether the proposed testing actually addresses the symptom and whether another condition may be contributing. The men’s guide covers common reasons these different hormone questions become mixed together.
TRT plus sermorelin is a combination, not an automatic upgrade
If a clinician proposes both, ask what condition each is intended to address, what evidence supports the combination, and how monitoring differs from treatment with one medicine. A before-and-after story involving several therapies cannot isolate the contribution of sermorelin.
Do not assume that more hormonal activity means better recovery or that one treatment cancels the risks of another. Bring all prescriptions to the same clinical review, including anything obtained through a second online service. See blends and stacks for the broader problem.
Enclomiphene and fertility are different questions again
Enclomiphene is associated with a different hormone-regulating pathway from sermorelin. A provider offering both does not establish that they serve the same purpose or that a combined program is appropriate. The exact medicine, regulatory status, and treatment goal need to be specified.
Tell the clinician if conception is a current or future goal. Testosterone therapy can be inappropriate when near-term fertility is desired, and a sermorelin add-on should not be assumed to protect fertility. Do not interpret a non-testosterone label as evidence of a fertility benefit.
Libido and sexual symptoms deserve a direct conversation
Changes in desire or sexual function can have hormonal and nonhormonal contributors. They should not be reduced to a promise that raising growth hormone will restore performance. Describe the symptoms, timing, other medicines, and relevant health conditions.
If treatment is proposed, agree on a relevant outcome and when to reassess. A change in IGF-1 does not establish that a sexual-health goal has been achieved. Read the labs guide and worth-it guide to prepare for that review.
The LifeMD review illustrates why a broader men’s health page needs to be read product by product.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Endocrine Society: Testosterone therapy guidelineClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- Hims: Does sermorelin increase testosterone?Primary or authoritative reference · Educational page; does not establish current product availability.
- Sinha et al.: Growth hormone secretagogues and male body compositionClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- Mayo Clinic: Sermorelin injection informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.